Elanco Animal Health's consensus analyst price target has increased from $21.18 to $21.91. This change reflects greater optimism among analysts about revenue growth and margin expansion prospects for the company.
Analyst Commentary
Recent analyst updates reflect a broadly optimistic sentiment toward Elanco Animal Health's near-term prospects. Analysts have raised their price targets, citing improving fundamentals and favorable comparisons to peers in the sector.
Bullish Takeaways- Bullish analysts now forecast that Elanco will outpace the market leader in growth by 2025, reflecting increased confidence in the company's execution and pipeline strength.
- Margin expansion is viewed as a significant opportunity. Elanco's current margins trail those of sector leaders, presenting room for substantial improvement and EBITDA growth.
- Survey work and data analysis suggest the market is underestimating Elanco's long-term EBIT margin potential. This supports the raised price targets.
- Expectations of continued EBITDA upside underpin a more favorable outlook. Analysts emphasize recent diligence and data as evidence of rising revenue and improving operational leverage.
What's in the News
- Elanco updated its 2025 guidance, raising expected full-year revenue to $4,645 million to $4,670 million but forecasting a wider net loss of $41 million to $56 million and an increased loss per share of $0.08 to $0.11 (Company Guidance).
- Fourth-quarter 2025 outlook includes revenue in the range of $1,085 million to $1,110 million with a projected net loss of $86 million to $100 million and loss per share of $0.17 to $0.20 (Company Guidance).
- Product label expansions were announced for two leading canine parasiticides, Credelio Quattro and Credelio, now including prevention of Lyme disease and treatment of additional tick infestations (Product Announcement).
- The FDA granted Emergency Use Authorization for Credelio (lotilaner) to treat New World screwworm in dogs, marking the first such EUA for this condition (Product Announcement).
- Important updates made to the U.S. Zenrelia label following additional FDA review, with continued emphasis on safety and guidance for vaccination timing in dogs treated with this JAK inhibitor (Product Announcement).
Valuation Changes
- Consensus Analyst Price Target has risen from $21.18 to $21.91, reflecting a modest increase in perceived fair value.
- Discount Rate has increased slightly, from 6.78% to 6.96%, which suggests a marginally higher risk premium applied by analysts.
- Revenue Growth estimates have edged up from 4.88% to 5.01%, showing improved expectations for top-line expansion.
- Net Profit Margin projections are up noticeably, from 3.75% to 4.82%, indicating greater confidence in future profitability.
- Future P/E ratio has declined significantly, from 67.0x to 52.8x, which points to lower anticipated valuation multiples for forward earnings.
Have other thoughts on Elanco Animal Health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.